Erivedge is a capsule taken once-daily to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or cannot be treated effectively with surgery or radiation. Erivedge works by blocking abnormal functioning of the Hedgehog cell signalling pathway. Abnormal activation of this pathway is responsible for tumour development in most basal cell carcinomas. Erivedge is approved in the US, EU, Switzerland and many other countries across the world.